• Marta Berndsen, Sara Renberg, Toto Hølmebakk, Emma Hancke, Florian Puls, Fredrik Karlsson, Stephan Stoldt, Bodil Bjerkehagen, Haglund de FlonFelixFDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.Department of Pathology and Cancer diagnostics, Karolinska University Hospital, Stockholm, Sweden., Andreas Muth, Andri Papakonstantinou, Kjetil Boye, and Stefan Lindskog.
• Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• Br J Surg. 2023 Nov 9; 110 (12): 185718621857-1862.

BackgroundGastrointestinal stromal tumour (GIST) is the most common intra-abdominal sarcoma. Risk classification systems, commonly the modified National Institutes of Health consensus criteria, identify tumour properties relating to patient outcomes. However, owing to limited long-term evidence, most guidelines recommend up to 10-year follow-up for all risk groups except very low-risk GIST.MethodsThis retrospective multicentre study included patients who had complete resection of primary, non-metastatic GIST from three Scandinavian sarcoma centres: Gothenburg (2004-2020), Stockholm (2000-2019), and Oslo (2000-2017). Medical records were reviewed for clinical details regarding diagnosis, treatment, and follow-up, and recurrence-free and disease-specific survival evaluated.ResultsThe total cohort consisted of 1213 patients with GIST. High-risk patients and those treated with tyrosine kinase inhibitors were excluded. The remaining 649 patients were included in the present analysis: 118 with very low-, 381 with low-, and 150 with intermediate-risk GISTs. Five-year recurrence-free survival rates were 100, 98.5, and 100 per cent for the intermediate-, low-, and very low-risk groups respectively (P = 0.246). Disease-specific survival rates 10 years after surgery were 100, 98.4, and 100 per cent for the intermediate-, low-, and very low-risk groups respectively (P = 0.262).ConclusionPatients with completely resected non-high-risk GISTs have an excellent long-term outcome, irrespective of risk group. Follow-up programmes to detect disease recurrences in these patients are probably not indicated.© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.

23 keywords...

hide…